Table 1.
Clinical and Biochemical Characterization of NAFLD Carrying HCC Patients Investigated
| Demographic data | |
| Patients, male/female, n | 27 (25/2) |
| Age, y | 71 (49–86) |
| BMI | 28.2 (22.3–34.6) |
| Clinical data | |
| Hypertension | 88.9% |
| Dyslipidemia, TG >150/HDL (<40 males/<50 females) | 70.4% |
| Diabetes mellitus | 85.2% |
| CHILD | A (59.3%) |
| Resection | 9/14 (64.3%) |
| OLT | 6 (22.2%) |
| MELD | 9 (6–14) |
| Biochemical data | |
| Triglycerides, mg/dL (nv, 50–150) | 111 (77–155) |
| AST, U/L (nv, 5–40) | 37 (17–83) |
| ALT, U/L (nv, 5–40) | 37 (13–86) |
| γ-GT, U/L (nv, 5–45) | 111 (14–307) |
| Bilirubin, U/L | 0.9 (0.3–2.5) |
| AFP, ng/mL (nv, <10) | 131.6 (1–2919) |
| Albumin, g/L | 4.1 (3.3–4.8) |
| Histologic data | |
| Steatosis score | 0 (18.5%) 1 (70.4%) 2 (11.1%) 3 (3.7%) |
| Ballooning score | 1 (45.5%) |
| Fibrosis score | 1 (40.9%) |
| Cirrhosis | 59.3% |
| NAS score | 1–3 (27.3%) |
| Oncologic data | |
| Nodules, n | 1 (1–3) |
| Dimensions, mm | 73 (7–180) |
| Edmondson–Steiner grading, 1–4 | 9 (6–14) |
NOTE. The values are expressed as medians and interquartile range. For histologic scores the range of variability is included.
AFP, alfa-fetoprotein; ALT, aspartate aminotransferase; AST, alanine aminotransferase; BMI, body mass index; γ-GT, γ-glutamyl transpeptidase; HDL, high density lipoprotein; MELD, Mayo End stage Liver Disease; nv, normal value; OLT, orthotopic liver transplantation; NAS, NASH Activity score; TG, triglycerides.